Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists.

Bonde, Tiago M; Garmo, Hans; Stattin, Pär; Nilsson, Per; Gunnlaugsson, Adalsteinn; Swanberg, Daniela; Robinson, David

Bonde, Tiago M; Garmo, Hans; Stattin, Pär; Nilsson, Per; Gunnlaugsson, Adalsteinn; Swanberg, Daniela; Robinson, David.

Afiliação

Bonde TM; Department of Urology, Ryhov Hospital, Jönköping, Sweden.
Garmo H; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Stattin P; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Nilsson P; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Sweden.
Gunnlaugsson A; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Sweden.
Swanberg D; Department of Surgery, Höglandssjukhuset, Eksjö, Sweden.
Robinson D; Department of Urology, Höglandssjukhuset, Eksjö, Sweden.

Acta Oncol ; 62(12): 1815-1821, 2023 Dec.

Article em En | MEDLINE | ID: mdl-37850633

Assuntos

Braquiterapia; Neoplasias da Próstata; Masculino; Humanos; Terapia Neoadjuvante; Neoplasias da Próstata/radioterapia; Terapia Combinada; Hormônio Liberador de Gonadotropina; Antagonistas de Androgênios/efeitos adversos

Palavras-chave

Prostate neoplasms; androgen antagonists; gonadotropin-releasing hormone; mortality; prognosis; radiotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Braquiterapia Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google